HUTCHMED(HCM) - 2022 Q4 - Annual Report

Exhibit 99.1 HUTCHMED Reports 2022 Full Year Results and Provides Business Updates Landmark licensing deal with Takeda for fruquintinib outside of China, bringing HUTCHMED up to US$1.13 billion, plus royalties, and demonstrating execution of the new global strategy Record Full Year 2022 oncology/immunology revenues driven by significant increase in China in-market sales of ELUNATE, SULANDA and ORPATHYSalongside clinical and strategic progress Company to Host Annual Results Call & Webcast Today at 9 p.m. HKT ...